Soleno Therapeutics (SLNO) Asset Utilization Ratio (2015 - 2026)

Soleno Therapeutics' (SLNO) quarterly Asset Utilization Ratio came in at 0.49 in Q1 2026, up 48.6% on a QoQ basis from 0.33 in Q4 2025.

Soleno Therapeutics (SLNO) Asset Utilization Ratio (2015 - 2026) Analysis & Trends

Soleno Therapeutics (SLNO) has 5 years of Asset Utilization Ratio data on file, last reported at 0.49 in Q1 2026.

On a quarterly basis, Asset Utilization Ratio changed N/A year-over-year to 0.49 in Q1 2026; TTM through Mar 2026 was 0.49, a N/A change from a year earlier, with the FY2025 full-year figure at 0.43, changed N/A from the prior year.
Asset Utilization Ratio for Q1 2026 stood at 0.49, up from 0.33 in the prior quarter.
Over the last five years, Asset Utilization Ratio for SLNO reached as high as 0.49 in Q1 2026 and fell as low as 0.11 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Asset Util. (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	0.69
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	0.47
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	0.37
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Soleno Therapeutics	874.25 Mn	618.67 Mn	93.41 Mn	0.49

Download Data